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Neuroendocrine integration, an integration of the nervous system and endo-
crine system as its name implies, plays a critical role in the reproductive system. 
However, less progress has been made in the particular effects of neuroendocrine 
on embryo implantation. Recently, some significant knowledges have been gained 
on the regulation of neuroendocrine in embryo implantation. This chapter will 
summarize the current state of knowledges about the impaction of neuroendocrine 
on embryo implantation and discuss potential strategy to get higher pregnancy rate 
and to reduce recurrent implantation failure (RIF) possibility through modulating 
the neuroendocrine systems.
Keywords: neuroendocrine systems, embryo implantation, recurrent implantation 
failure, IVF-ET
1. Introduction
The success of mammalian pregnancy is mostly due to the smoothly embryo 
implantation into the maternal endometrium/decidua, which is a finely regulated 
process and requires the adaptation of maternal function to the needs of develop-
ing fetus. Human embryo implantation is a complex series of events involving 
blastocyst attachment, adhesion, and invasion into the endometrial tissue. Under 
normal circumstances, in order to ensure the consistency of this series, the blasto-
cyst-stage embryo and the uterine endometrium must be collaborated during the 
“window of implantation” [1]. It has been long established that neuroendocrine is 
indispensable for mammalian reproduction [2], in which the neuroendocrine cell 
can synthesize and release various hormones into gonadal organ after receiving 
neuronal signal. Notably, the hypothalamus is the metronome of reproduction, 
and its main function is to receive neural signals from the brain and transform 
these neural signals into an endocrine output, the pulsatile release of GnRH, and 
other related factors. The pituitary gland, as a link between the brain and other 
neuroendocrine-related organs, is divided into two lobes. For the anterior lobe, 
it is related to the regulation of the hypothalamic-pituitary-gonadal axis (HPG 
axis), hypothalamic-pituitary-thyroid axis (HPT axis), and hypothalamic-pitu-
itary-adrenal axis (HPA axis). For the posterior lobe, it is mainly about the regula-
tion of the hypothalamic-neurohypophysis system [3]. Therefore, the description 
of an importance of the neuroendocrine to implantation from the aspects above is 
an enormous and necessary work.
Infertility affects millions of couples worldwide and its treatment has progressed 
immensely. As one of the most prevalent approaches of treating infertility, in vitro 
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fertilization and embryo transfer (IVF-ET) is always confronted with recurrent 
implantation failure [4], which is in the means of the situation when the transferred 
embryo repeatedly, failed to implant after IVF-ET [5]. A strong association between 
pregnancy rate following IVF-ET and recurrent implantation failure has been 
investigated [4], but less studies mention directly about the role of neuroendocrine 
in recurrent implantation failure. A thorough understanding of the processes 
governing human embryo implantation would be of significant benefit for the 
treatment of infertility. Hence, this review provides a summary of current empiri-
cal researches on the impacts of neuroendocrine aspects in implantation so that we 
more understand the maternal environment at the time of embryo implantation 
and might optimize it by altering neuroendocrine regulation to increase the success 
rate after IVF-ET.
2. Hypothalamic-pituitary-gonadal axis
An integrated hypothalamic-pituitary-gonadal axis with several main actors 
including the gonadotropin-releasing hormone (GnRH), the gonadotropins 
(luteinizing hormone (LH) and follicular-stimulating hormone (FSH)), and the 
gonadal hormones are recognized as a key mechanism on human reproduction 
[6]. Hypothalamic gonadotropin-releasing hormone, as a crucial regulator of the 
HPG axis, with characteristic pulsatile secretion pattern, plays a dominant role in 
the endocrine control of reproduction and its possible effects on implantation by 
regulating downstream hormones which have been widely concerned so far [7]. 
Two GnRH molecules termed GnRH I (default as GnRH) and GnRH isoform II 
(GnRH II) can be found in humans, and both of them play an important role during 
the implantation period as shown in Figure 1 [6, 8].
Figure 1. 
Schematic of the HPG axis functions in implantation.
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2.1 GnRH functions in implantation via the pituitary-gonadal axis
In the HPG axis, after releasing from the hypothalamus in a pulsatile manner, 
GnRH then binds to GnRH receptors (GnRHRs) on the pituitary gland, in response, 
that LH and FSH are synthesized and secreted in pulse by the pituitary to match the 
GnRH signal. Subsequently steroid hormones including progesterone and estrogen 
are released from the gonads and form a loop by exerting a positive or a negative 
feedback effect on GnRH releasing and gonadotropin [8]. Although it has been 
reported that human type II receptor for GnRH II shows specific expression of the 
receptor in the anterior pituitary and it also has been suggested that these receptors 
might act together to regulate the biosynthesis and secretion of both LH and FSH, 
further investigation should be completed [9, 10]. Thus here, we focus on the func-
tions of GnRH in implantation via the pituitary-gonadal axis. Since natural GnRH 
has a short half-life, several GnRH synthetic analogues have been developed includ-
ing agonists and antagonists, which can be used to stimulate or block, respectively, 
the pituitary-gonadal axis in an assisted reproductive technology (ART), particu-
larly often applied to prevent premature LH surge [11]. In women undergoing 
IVF, GnRH agonist may improve the luteal phase support, used to trigger the final 
oocyte maturation and to improve implantation and live birth rates [12]. Although 
the effects of embryo implantation are still controversial, both of them are thought 
to tightly correspond to the pituitary-gonadal axis and eventually result in the 
fluctuation of the estrogen and progesterone level [6, 11].
Estrogen and progesterone regulate uterine cell proliferation and are necessary 
for the changes in both the blastocyst and uterine epithelium for successful adhe-
sion, so an imbalance between estrogen and progesterone during the luteal phase 
may lead to implantation defects [13]. Thus, it is quite clear that a deep understand-
ing of the action of estrogen and progesterone on the human endometrium will 
allow a clear insight into the mechanism of determining endometrial receptivity in 
embryo implantation.
So far, the molecular mechanism of estrogen regulation of maternal uterus 
in implantation remains unclear. Some studies implicated that estrogen was not 
essential for embryo implantation due to its receptor disappearance at the time of 
implantation [14, 15]. However, some studies believed that only after sufficient 
exposure to estrogen could progesterone exposure drive the endometrial receptivity 
to embryo implantation in a brief period [16, 17]. In addition, it has been proven 
that early growth response 1 (Egr1) as the downstream target is regulated by estro-
gen expression via leukemia inhibitory factor-signal transducer and activator of 
transcription 3 (LIF-STAT3) signaling pathway in the uterus of a mouse, and it fur-
ther regulates stromal cell decidualization by regulating Wnt4 [18]. Furthermore, 
some studies suggested that estrogen was a trigger to close the window of implanta-
tion via insulin-like growth factor 1 pathway and made the endometrium “recep-
tive” for blastocyst implantation [19, 20].
Progesterone production reaches its peak during the mid-luteal phase of the 
cycle, and this is the time when the secretory endometrium is appropriately pre-
pared for the implantation of an embryo [8]. During the luteal phase, progesterone 
is produced, in turn stimulating the proliferation of the lining of the uterus to 
prepare for implantation by blocking the production of matrix metalloproteinase 
(MMP) and stimulating the production of tissue factor (TF) and plasminogen 
activator inhibitor 1 (PAI-1) [21, 22]. The phenomenon that a luteal phase support 
with progesterone can improve the implantation and pregnancy rates indicates 
lower progesterone and lower implantation [23, 24]. A review by Yoshinaga further 
confirms that progesterone is also an indispensable factor for successful implanta-
tion and pregnancy maintenance [19].
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2.2 GnRH functions in implantation via peripheral reproductive tissue
The expression of GnRH/GnRH receptor (GnRHR) system and GnRH II in the 
female reproductive tissues has been widely reported. Therefore, in addition to 
its well-known function on the HPG axis, GnRH and GnRH II may also regulate 
extrapituitary reproductive tissues through the local GnRHRs [24]. Both GnRH 
and GnRH II have a dynamic pattern during the process of implantation; they may 
regulate the procedure of trophoblast local invasion and embryo implantation 
through the regulation of the proteolytic degradation of the extracellular matrix 
of the endometrial stroma and the motility of decidua endometrial stromal cells 
[6]. During the luteal phase of the menstrual cycle, high levels of both GnRH and 
GnRHR are expressed in the endometrium; thus the blastocyst will prefer to attach 
the endometrial epithelial surface and go through implantation [5, 7]. In mammals, 
the distribution of GnRH II is more wide in peripheral tissue than that of GnRH I,  
which hypothesized that GnRH II has extra functions and a possible regulator 
in endometrial environment [9]. Huang et al. found that GnRH II could directly 
regulate the behavior of endometrial cells. An embryo implantation failure may 
be due to the dysfunction of human decidual endometrial stromal cell motility via 
different pathways [25]. The hallmark events of implantation are represented by 
tissue remodeling and angiogenesis, which are regulated by the activity of MMPs 
and tissue inhibitors of MMPs (TIMPs) [26]. It has been demonstrated that GnRH 
II may contribute to the regulation of the cell motility of decidual endometrial 
stromal cells via the binding of GnRH-IRs, in turn stimulating the expression of 
MAPK-mediated proteinases MMP-2 and MMP-9, which specifically degrade the 
basement membrane and then facilitate the invasion and migration of decidual 
endometrial stromal cells [6].
Given the evidence above, no matter via the GnRHR in the pituitary-gonadal 
axis or via GnRHR in peripheral reproductive tissue, both pathways of GnRH func-
tions on implantation are potential candidate therapeutic targets for improving the 
embryo implantation rate in the treatment of infertility.
3. Hypothalamus-pituitary-adrenal axis
In addition to the well-established role of the HPG axis in implantation and 
infertility, the role of the hypothalamic-pituitary-adrenal axis (HPA axis) in the 
reproductive tract also cannot be neglected. A hormone cycle also exists in the HPA 
axis. After receiving neuronal signals, the corticotropin-releasing hormone (CRH) 
secreted from the hypothalamus transports to function in the pituitary gland to 
release adrenocorticotropic hormone (ACTH) and subsequently acts on the adrenal 
cortex to produce glucocorticoid (GC) hormones (mainly cortisol in humans). 
Eventually, the glucocorticoid hormones will act back on the hypothalamus and 
pituitary (to suppress CRH and ACTH production) in a negative feedback cycle [3]. 
The hormone within the HPA axis can act at different levels of the HPG axis as well 
as the uterus and other peripheral tissues; therefore we will discuss it in the follow-
ing part, respectively.
3.1 CRH functions in implantation
CRH is taking the lead in the HPA axis, and its expression is mediated by 
its membrane receptors including CRH-R1 and CRH-R2 [27]. According to the 
research, upregulating gal-1 expression by acting through the CRHR1 in Ishikawa 
cell line and macrophages indeed indicates that CRH plays a critical role in 
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implantation [28]. CRH has tremendous effects on implantation since it can impact 
the HPG axis at different levels. In mammals, numerous GnRH-containing neurons 
in the hypothalamus have been found to express both CRH receptors (CRH-R1, 
CRH-R2) which can exert an estradiol-dependent effect of directly influencing 
GnRH release in mice and rats, leading to a comparable change in serum LH levels, 
and eventually contribute to the difference of response during implantation proce-
dure [29].
Besides, CRH serving as an autocrine and paracrine modulator is expressed in 
peripheral tissue of the female reproductive system, including the endometrium 
[30]. Early pregnancy, containing a higher concentration of CRH in the endome-
trium of a rat and killing activated T lymphocytes, can promote implantation and 
maintain pregnancy [31]. Furthermore, CRH can downregulate the expression 
of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) by 
extravillous trophoblast cells, thereby controlling proper trophoblast invasion dur-
ing implantation [32].
3.2 ACTH functions in implantation
Besides the downstream effects from CRH, ACTH also has its certain effects in 
implantation, though fewer studies have been investigated. Similar to CRH, chronic 
ACTH stimulation also impacts on the HPG axis by inhibiting LH secretion to 
impair the procedure of implantation. In the contrary, acute ACTH treatment may 
result in a rapid increase of progesterone which will lead to a positive feedback and 
induce the elevation of LH and FSH within the HPG axis [33]. A reference implied 
that exogenous ACTH produced postponed implantation effects and resulted in 
the high incidence of miscarriage and embryonic resorption [34]. However, further 
investigation should be performed.
3.3 Glucocorticoid functions in implantation
Glucocorticoid (GC) is a measurement of stress and leads to well-characterized 
profound reproduction function by suppressing the HPG axis and influencing the 
peripheral tissue [35]. Some studies indicated that maintaining the administration 
of glucocorticoids could improve pregnancy rates and outcomes both in animals 
and human beings [36, 37]. Therefore, to elucidate the role of glucocorticoids in 
implantation, the following two dimensions will be depicted.
3.3.1 Via the HPG axis
As a pivotal hormone in the HPA axis, GC has been demonstrated with the 
function of decreasing the release of GnRH from the hypothalamus, both directly 
and indirectly inhibiting GnRH pulses or inhibiting upstream regulators of GnRH 
release, in turn exerting direct effects on the anterior pituitary of the release of the 
gonadotropins, eventually influencing the steroid hormones from gonads [38].
GnRH-containing neurons also express glucocorticoid receptors (GRs) and have 
an effect of directly inhibiting GnRH release in mice and rats, leading to a decrease 
of serum LH [39]. Besides, evidences showed that chronic corticosterone (CORT) 
treatment could inhibit directly GnRH release in the hypothalamus and influence 
on implantation and reproduction [29, 40]. Another method is via modulating the 
hormones upstream of GnRH, mainly including kisspeptin (KISS1) and RFamide-
related peptide-3 (RFRP-3) [41]. Both of these two hormones express GRs, imply-
ing that they could potentially respond to GC and suppress the release of GnRH, 
leading to the fluctuation of LH and FSH from the pituitary [42].
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In addition to the secondary signaling effects on the pituitary, glucocorticoid can 
directly inhibit its secretion by different mechanisms at the level of the pituitary, 
including modulating the sensitivity of the pituitary to changes in GnRH secretion 
and further decreasing the synthesis and secretion of LH and FSH from the pitu-
itary [43]. However, a study showed that the effects of glucocorticoid directly on 
the pituitary in secretion and synthesis were highly variable [44]; thereby further 
studies should be performed in this field.
The gonads, as the lowest level in the HPG axis, are another crucial component 
for glucocorticoids to regulate, which GC exhibits both stimulatory and inhibitory 
effects on it [45]. GC can modulate the expression of the LH receptor (LHR) on the 
gonads, and it also can inhibit the synthesis of testosterone (T), estrogen (E2), and 
progesterone (P). Hence, it can easily dysregulate these signals and cause profound 
fertility problems in both ovarian function during ovulation and uterine function 
during fertilization, implantation, and pregnancy [43].
3.3.2 Via the peripheral tissue
In addition to the effects of GC and GR on the central nervous system, 
GR expression also has been demonstrated in the peripheral tissue [35]. 
Mifepristone, a potent high-affinity GR antagonist, also implied the effects of 
GC regulating embryo attachment and invasion [46]. However, direct evidence 
implicating GR signaling in uterine biology has been described only recently. 
The study suggested that decreased blastocyst implantation rate and subsequent 
defects in stromal cell decidualization were found out in a uterine-specific gluco-
corticoid receptor (GR) knockout (uterine GR KO) mouse. As a master regulator, 
GC repressed some important gene expression and eventually influenced the 
uterine environment [35].
4. Hypothalamus-pituitary-thyroid axis
There are three dominant hormones within the hypothalamus-pituitary-thyroid 
axis (HPT axis), such as thyrotropin-releasing hormone (TRH), thyrotropin-
stimulating hormone (TSH), and thyroid hormone (TH: T3 and T4) [3]. When it 
comes to pregnancy accompanied with thyroid disease, we always ascribe subfertil-
ity and recurrent miscarriage to either hypothyroidism or hyperthyroidism [47]. 
In in vivo studies, it has been demonstrated that hypothyroidism might have a dual 
effect on pregnancy, by influencing implantation at a very early stage and regulat-
ing placental development at the later stage [48]. Moreover, thyroid hormone 
receptors, expressed in the endometrium and trophoblast during implantation, can 
influence the feto-maternal interface [49]. In in vitro studies, it has been proven 
that TH is involved in the bidirectional cross talk between the blastocyst and 
endometrium during implantation. In hypothyroid females, lower levels of both 
ISP1 and ISP2 (two key regulators of embryo implantation) could be found in the 
uterus [48]. Furthermore, TH impacts both the endometrium and the trophoblast, 
via either directly or indirectly through TH effects on the synthesis and activity of 
implantation-mediating molecules [50]. Although a research indicated that when 
TSH value was below 2.5 mIU/L, no association varying TSH values and implanta-
tion was detected [51]. TH receptors (TRs) and TSH receptors (TSHRs) were 
broadly presented in the feto-maternal unit [50] and even increase the expression 
of TSHR, TRa1, TRa2, and TRb1 in endometrial cells during peri-implantation [52]. 
Moreover, TH synthesis is related to several transcripts, including prolyl 4-hydroxy-
lase beta (P4HB), a molecular chaperone involved in endocytosis of immature 
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thyroglobulin (Tg) molecules, thyroid peroxidase (TPO), and Tg, which also could 
be discovered in the endometrium [53].
Beyond that, hypothyroidism can result in development of reduced endometrial 
thickness, because of reducing the uterine cells’ estrogenic response [54]. In addi-
tion to affecting the proliferation and maturation of endometrial tissue, TH also 
could have profound effects on the regulation of the HPG axis and subsequently on 
implantation [55]. Angiogenesis and endometrium remodeling are considered as 
pivotal events for successful implantation, decidualization, and placentation, while 
it has been demonstrated that TH can exert an important role in angiogenesis via 
both genomic and non-genomic mechanisms in a variety of animal models [56]. 
Besides, TH regulates integrin ανβ3, a class of cell adhesion molecules (CAMs) 
that interacts with extracellular matrix (ECM) ligands, matrix metalloproteinases 
(MMPs), and other CAMs, playing a critical role in the cascade of events to success-
ful implantation [57].
In summary, it is clearly suggested that both TSH and TH are essential players in 
the mechanism of regulating implantation based on current experimental and clini-
cal evidences. However, less evidence shows the influence of TRH on the implanta-
tion procedure; thus further exploration needs to be continued.
5. Hypothalamo-neurohypophyseal system
Hormones from the posterior lobe of the pituitary also play an essential role in 
neuroendocrine and implantation. The hypothalamo-neurohypophyseal system 
is composed of the hypothalamus and posterior pituitary, regarded as the site 
for secretion of neurohypophysial hormones, classically including oxytocin and 
vasopressin [58].
It is well established that apt uterine contractile activity uterus is vital to suc-
cessful implantation, and it has been proven that both oxytocin and vasopressin 
receptors are expressed in the uterus, which are closely relevant to the contractile 
activity of the uterus [49]. Both oxytocin and vasopressin receptors belong to the 
class I family of G-coupled receptors, regulating uterus contraction via a central 
or peripheral pathway [59]. So far, massive research literature indicated that 
oxytocin and vasopressin antagonist treatment was effective in priming of the 
uterus for implantation and consequently improved the implantation rate after 
IVF [58, 60–62].
Atosiban, a mixed vasopressin V1a and oxytocin receptor antagonist, have 
been demonstrated to improve uterine receptivity, provide a decrease in uterine 
contractile activity, and increase endometrial blood perfusion in women under-
going embryo transfer [58]. Another important effect of atosiban is to decrease 
endometrial perfusion and embryonic survival rate by inhibiting the stimulation of 
the endometrial production of prostaglandin F2a in an animal model [63]. With the 
beneficial of improving uterine environment, atosiban can be a specific treatment 
for the improvement of implantation rate following IVF-ET [64]. Thereby, the novel 
class of drugs based on these two receptors and its relative pathway for improving 
implantation rate and pregnancy outcomes still need to be further explored.
6. Neuroendocrine systems improve implantation rate in IVF-ET
Infertility gradually becomes an epidemic problem and brings an enormous 
burden on about 10% of the couples in child-bearing age [65]. Implantation con-
cerns frequently arise in couples with infertility, especially in the setting of assisted 
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reproductive technology (ART) cycles [4]. Regardless of the impressive develop-
ment in ART, there are still approximately 10–15% of the infertile couples suffering 
from recurrent implantation failure (RIF) [2].
According to the literature, factors involved in recurrent implantation failure 
can be summarized in three aspects such as decreased endometrial receptiv-
ity, defective embryonic developments, and others [2, 4]. However, only the 
evidence about different axes of hormones from neuroendocrine influencing 
the procedure of implantation has been concluded in this paper, and it mainly 
focuses on the aspect of decreasing maternal endometrium receptivity but less 
on blastocyst (Table 1).
Furthermore, the relevant literatures of ACTH, TRH, as well as TSH on implan-
tation procedure are less, and their mechanisms are not elaborated enough. Hence, 
studies aiming to better define the association between neuroendocrine system and 
implantation processes should be further investigated, which may lead to further 
therapeutic intervention, thereby optimizing embryo implantation and eventually 
improving the success rate following IVF-ET.
Table 1. 
Mainly aspects of neuroendocrine hormones involved in improving the condition of RIF.
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